Role of core protein mutations in the development of occult HBV infection.

J Hepatol

Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China. Electronic address:

Published: June 2021

Background & Aims: Occult HBV infection (OBI) is associated with transfusion-transmitted HBV infection and hepatocellular carcinoma. Studies on OBI genesis have concentrated on mutations in the S region and the regulatory elements. Herein, we aimed to determine the role of mutations in the core region on OBIs.

Methods: An OBI strain (SZA) carrying 9 amino acid (aa) substitutions in the core protein/capsid (Cp) was selected by sequence alignment and Western blot analysis from 26 genotype B OBI samples to extensively explore the impact of Cp mutations on viral antigen production in vitro and in vivo.

Results: A large panel of 30 Cp replicons were generated by a replication-competent pHBV1.3 carrying SZA or wild-type (WT) Cp in a 1.3-fold over-length of HBV genome, in which the various Cp mutants were individually introduced by repairing site mutations of SZA-Cp or creating site mutations of WT-Cp by site-directed mutagenesis. The expression of HBcAg, HBeAg, and HBsAg and viral RNA was quantified from individual SZA and WT Cp mutant replicons in transfected Huh7 cells or infected mice, respectively. An analysis of the effect of Cp mutants on intracellular or extracellular viral protein production indicated that the W62R mutation in Cp had a critical impact on the reduction of HBcAg and HBeAg production during HBV replication, whereas P50H and/or S74G mutations played a limited role in influencing viral protein production invivo.

Conclusions: W62R and its combination mutations in HBV Cp might massively affect HBcAg and HBeAg production during viral replication, which, in turn, might contribute to the occurrence of OBI.

Lay Summary: Occult hepatitis B virus infections (OBIs) have been found to be associated with amino acid mutations in the S region of the HBV, but the role of mutations in the core protein (Cp) remains unclear. In this study, an OBI strain (SZA) carrying 9 amino acid substitutions in Cp has been examined comprehensively in vitro and in vivo. The W62R mutation in Cp majorly reduces HBcAg and HBeAg production during HBV replication, potentially contributing to the occurrence of OBI.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2020.12.023DOI Listing

Publication Analysis

Top Keywords

hbcag hbeag
16
hbv infection
12
amino acid
12
hbeag production
12
mutations
10
core protein
8
hbv
8
occult hbv
8
mutations region
8
role mutations
8

Similar Publications

Rationale: Mass vaccination, low cost of immunoglobulins, and new drugs led to the emergence of new, unusual patterns of hepatitis B serum markers. This study reported a rare case of hepatitis B with all 5 positive serum markers, including HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb.

Patient Concerns: A 30-year-old female patient was admitted due to abnormal liver function.

View Article and Find Full Text PDF

Objectives: Hepatitis B virus (HBV) has a partially double-stranded circular deoxyribonucleic acid (DNA) that replicates through reverse transcription, producing an intermediate ribonucleic acid (RNA). This replication process has a high chance of error, leading to several mutations in the genome. According to several studies conducted worldwide, the classical basal core promoter (BCP) double mutation (A to T at nucleotide 1762 and G to A at nucleotide 1764) in the BCP region and the mutation in the precore (PC) region (G to A at nucleotide 1896) of HBV DNA have a strong correlation with advanced liver disease.

View Article and Find Full Text PDF
Article Synopsis
  • A study involving 80 patients with chronic hepatitis B (CHB) found that 15% experienced virologic breakthrough (VBT) after switching from nucleos(t)ide analogue (NA) therapy to pegylated interferon alpha (Peg-IFN-α) treatment.
  • Patients who had higher levels of HBcrAg (≥5 logU/mL) and HBsAg (≥100 IU/mL) showed a significantly increased risk of VBT and were less likely to achieve HBsAg clearance post-therapy.
  • The research indicates that monitoring HBcrAg and HBsAg levels can provide insights into immune responses and help prevent VBT, potentially improving the chances of achieving a functional cure for CH
View Article and Find Full Text PDF

Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B.

Virulence

December 2024

Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.

Predicting hepatitis B surface antigen (HBsAg) clearance is important for chronic hepatitis B (CHB) patients receiving pegylated interferon-alfa (Peg-IFN) therapy. We aimed to determine the predictive value of serum hepatitis B core antibody (anti-HBc) for HBsAg clearance. A total of 189 HBeAg-negative CHB patients who received Peg-IFN based therapy were retrospectively included and classified into two groups: nucleos(t)ide analogues (NAs) add-on Peg-IFN group (add-on group,  = 94) and Peg-IFN combined with NAs or Peg-IFN monotherapy group (combination or monotherapy group,  = 95).

View Article and Find Full Text PDF

Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion.

JHEP Rep

September 2024

Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing, China.

Article Synopsis
  • The study investigates how the expression and secretion of HBsAg from integrated HBV DNA affect the ability to achieve a functional cure for chronic hepatitis B.
  • It analyzes liver biopsy samples from 625 patients, including treatment-naive and functionally cured individuals, to compare HBsAg levels and explore the mechanisms behind HBsAg secretion differences in HBeAg-positive versus negative patients.
  • Results show that HBeAg-negative patients have lower serum HBsAg but similar intrahepatic levels, with impaired secretion linked to an increase in preS1 mRNA from integrated HBV DNA, disrupting the balance in transcriptional activity of related promoters.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!